aceRNA Technologies
aceRNA Technologies is a biotech startup focused on developing novel genetic therapies using proprietary RNA design technology, including RNA Switch™. The company's mission is to contribute to regenerative medicine and drug development by discovering active microRNAs and creating targeted mRNA medicines that regulate therapeutic effects in a cell-specific manner. They aim to develop innovative treatments such as smart mRNA drugs, in vivo cell reprogramming, and gene regulation therapies, leveraging their unique RNA Switch technology to address safety and efficacy challenges in gene and cell therapies.
Industries
Nr. of Employees
small (1-50)
aceRNA Technologies
Innovation Hub Kyoto, 46-29 Yoshidashimoadachi-cho, Sakyo-ku, Kyoto 606-8304 JAPAN
Products
Cell selection / sorting reagent based on RNA-responsive regulatory elements
Research reagent that identifies or enables removal/selection of specific cell types using RNA-responsive regulatory elements integrated into constructs (suicide or selection strategies) to allow enrichment without specialized sorting machinery.
Selectable marker mRNA products for cell selection
mRNA reagents encoding drug-resistance markers for use as selectable markers in transfection workflows (examples described include puromycin, blasticidin and hygromycin resistance marker mRNAs).
Cell selection / sorting reagent based on RNA-responsive regulatory elements
Research reagent that identifies or enables removal/selection of specific cell types using RNA-responsive regulatory elements integrated into constructs (suicide or selection strategies) to allow enrichment without specialized sorting machinery.
Selectable marker mRNA products for cell selection
mRNA reagents encoding drug-resistance markers for use as selectable markers in transfection workflows (examples described include puromycin, blasticidin and hygromycin resistance marker mRNAs).
Services
Joint R&D projects with external partners to apply miRNA-guided expression control to mRNA, viral, and cell therapies, including scientific discussion, construct design, screening, and preclinical validation.
Joint R&D projects with external partners to apply miRNA-guided expression control to mRNA, viral, and cell therapies, including scientific discussion, construct design, screening, and preclinical validation.
Expertise Areas
- mRNA therapeutic development
- miRNA activity discovery and profiling
- Synthetic RNA design for expression control
- Cell therapy process optimization and safety control
Key Technologies
- Synthetic mRNA engineering
- miRNA activity profiling
- RNA-based ON/OFF regulatory switches
- High-throughput screening (NGS, fluorescence imaging)
News & Updates
aceRNA Technologies announced the closing of a 960 million JPY Series B round to fund the development of targeted mRNA medicines and new therapeutic approaches.
aceRNA Technology and Pfizer collaborated to engineer RNA switch for potential targeted mRNA medicines.
aceRNA Technologies was selected as a finalist in the Japan Innovation Bloom Grant Call 2022.
aceRNA Technologies announced the closing of a 960 million JPY Series B round to fund the development of targeted mRNA medicines and new therapeutic approaches.
aceRNA Technology and Pfizer collaborated to engineer RNA switch for potential targeted mRNA medicines.
aceRNA Technologies was selected as a finalist in the Japan Innovation Bloom Grant Call 2022.